How To Optimize Your Advanced Therapy Manufacturing Process Before You Automate

Scaling cell therapy production and processing is crucial for reducing costs and ensuring a consistent supply, which in turn encourages future investment. While automation is often viewed as essential for cutting labor expenses (which can constitute nearly 50% of costs), it's not always the immediate priority. Automating inefficient or "wasteful" workflows can create rigid, unscalable processes, leading to significant financial drawbacks during commercialization.

This presentation delves into key unit operations such as expansion, harvest, separation, and cryopreservation. Through case studies, we illustrate how deploying phase-appropriate tools and fostering collaboration with suppliers and service providers can directly impact costs and accelerate development timelines, often without requiring major capital expenditure or immediate automation.

Learning Objectives:

• Tailor your ATMP tools with investments appropriate for each development phase, ensuring seamless scalability from research (RUO) to manufacturing (cGMP).
• Understand how contract service providers can minimize costs and waste in areas like separation, product contact material selection, and process optimization.
• Explore recently optimized tools specifically designed for ultra-low temperature (ULT) applications, particularly at −86°C and colder.